Rifampicin resistance of My cobacterium Zeprae is a potential threat to the success of multidrug therapy (MDT). However, the prevalence of leprosy caused by rifampicin resistant organisms is unknown. The mouse footpad assay of the drug susceptibility of M. Zeprae is not generally available, and a complete survey employing this method is not possible, because the need for fresh biopsy specimens containing large numbers of organisms for inoculation of the footpad means that only a small proportion of all patients can be tested.
of the double mutation. Two of the five strains that had been obtained as bopsy specimens demonstrated resistance-associated mutations; these had been obtained from patients whose bacterial index had not fallen after 24 doses of MDT. Four strains obtained ;lS isolates in the mouse footpad, with serine to phenylalanine mutations, were three strains that had been passaged 5-14 times over the past 5-10 years, and one primary isolate from a new, untreated LL patient. All of the strains that had been obtained from mice had earlier be �n demonstrated to be susceptible to rifampicin administered in a dosage of 10 mg per kg body weight.
The line-probe assay proved to be a successful method for detecting rifampicin resistance in a field setting in Nepal. Of concern, however, was the finding that mutati(us had occurred in apparently susceptible strains. We have extended these observations by testing isolates both by the line-probe assay, and in mice administered rifampicin in dosa. �es of 5 mg and 10 mg per kg. It is possible that this powerful genetic technique is capa Jle of detecting rifampicin-resistant M. leprae that are susceptible to clinical doses of rifampicin.
DISCUSSION
Dr Colston: To your knowledge, are there any reports of this mutation not conferring resistance to rifampicin on M. tuberculosis?
Dr Roche: In the case of M. tuberculosis, mutations in various portions (, f the rpoB-gene confer different levels of resistance, and mutations at this position in the M. tt!berculosis gene produce high levels of resistance.
Professor Grosset: The important issue is the presence of mutations ill the rp oB-gene without clinical evidence of resistance to rifampicin. Have you en COUll tered any such instances?
Dr Roche: What we have shown are strains of M. leprae in which mutal ions are present that do not demonstrate resistance in mice. We believe the explanation of the highly resistant strains that you have described to be the presence of additional mutations in other portions of the gene that we have not probed.
Profe s � or larlier (Bacteriologie et Hygiene, Faculte de Medecine Pitie -Salpetriere, 91 boulevard de l'Hopital, 75634 Paris Cedex 13, France): We have studied 83 bi opsy specimens obtained from 77 patients. All were patients with MB leprosy; 43 were patienl s in relapse, and 34 were newly diagnosed. For all but three specimens, which arrived in (Iur laboratory 2 weeks after the biopsy had been performed, the susceptibility to rifampicin of the strains of M. leprae was tested in mice by the weekly administration of 10 mg rifampicin per kg body weight by gavage. M. Zeprae from all of the specimens were subjected to thf' molecular test, which consisted of sequencing a 45-codon segment of the rp oB-gene. Betwee l 50 and 60% of the strains multiplied in mice, whereas the molecular test was carried out for more than 90% of the strains. Results from 45 patients were obtained both in mice and from PCR; 34 strains, 18 from relapses, and 16 from newly diagnosed patients, were determined to be susceptible to rifampicin in mice, whereas 11 strains, all from relapses, were found in miC!: to be resistant. Mutations in the rp oB gene were found in the PCR products of all of the resis :ant and none of the susceptible strains.
Dr Daumerie: Did the relapses occur after treatment with standard MDT? Professor la rlier: Virtually all of the relapses occurred after treatrnent with other regimens.
Dr Roche: What was the nature of the other regimens?
Professor Grosset: We have not observed a single instance of rifampicin resistance among patients who received standard MDT. All of the relapses occurred after what was really monotherapy with rifampicin.
Dr Roche: The apparent contradiction between the results of my study and your results probably lies in the treatment of the patients. I suggest that rifampicin monotherapy selects mutants with a high level of resistance, whereas MDT selects those with only a clinically insignificant level.
Professor farlier: I agree that the way in which the resistant mutants were selected in the patients may have been different in our two studies. However, shouldn't one expect a strain carrying the mutation most frequently observed in rifampicin resistant strains of both M. leprae and M. tuberculosis be accompanied by clinical evidence of resistance?
Professor fi: The available data appear to demonstrate that resistance to rifampicin is single-step resistance. How, then, is it possible that you find varying levels of resistance in Nepal? On another matter, how good is the evidence that, on the basis of demonstrating mutations in the rp oB gene, we can diagnose rifampicin resistance in the field?
Dr Roche: Until we have validated our observations in Nepal among patients receiving standard MDT, we cannot be certain that our tools are adequate. Our present method appears to demonstrate resistance among patients who respond quite well to the MDT. Dr Colston: Is it possible that, in Nepal, you are dealing with mixtures of resistant and susceptible strains of M. leprae? Dr Cole: I find it difficult to understand Dr Roche's observations. All of the previously encountered strains of M. leprae that carry the serine to phenylalanine substitution at the 531 position showed resistance at 10 mg per kg. Also, in all other bacterial species in which this mutation has been described, the mutant strains are highly resistant. The mouse work should probably be repeated. And the possibility of a mixed population of organisms should be investigated.
Professor Grosset: A relapse during treatment with rifampicin occurs because the great majority, if not all, of the organisms are resistant. Rifampicin is so actively bactericidal that all of the susceptible individuals in a population of M. leprae are killed. This is indeed .the case in tuberculosis. Therefore, a mixture of susceptible and resistant strains appears unlikely indeed.
Dr Daumerie: Many experts have identified monitoring of rifampicin as a high priority for research. Can the experts here tell us whether the technique is reliable, or is more time required for development? And, if so, how much time?
Professor Grosset: I cannot qualify as an expert in molecular biology. However, from the work at the Pasteur Institute and that described by Professor Iarlier at the Pitie-Salpetriere, and also from that in Nepal, I believe we now have enough information to proceed to implement a programme based on these molecular techniques that is designed to detect rifampicin resistance. What technique should be employed?
Dr Noordeen: I think the problem lies in having two rather different situations-one, in which patients have been treated in a rather artificial setting by a variety of regimens, and the other, in which patients have been treated with standard MDT in a natural setting. Our objective is to mount surveillance of rifampicin resistance in the framework of leprosy control programm es. Dr Roche's data, resulting from a study carried out in such a natural setting, cast some doubt on the specificity of the test. Can the test be improved? Or can we try not to dilute its specificity by restricting the variety of cases chosen for screening? I suggest, as the criterion for screening, a patient who has relapsed after standard MDT, and who has failed to respond to retreatment.
Professor Grosset: I agree with Dr Noordeen in part. If we wish to demonstrate that treatment by MDT does not create resistance to rifampicin, a phenomenon that has yet to be reported, we should undertake a study designed to confirm this. I think that this would be important to WHO.
Professor Ii: The first signs of rifampicin resistance would be cases of acquired resistance. Therefore, we should screen only MB patients who had completed MDT at least four or five years earlier, and whose skin smears show a BI 2:3+.
Dr Noordeen: I think it important to apply the technique only to the few patients likely to harbour rifampicin resistant strains of M. leprae, and not to dilute the study by testing the very large numbers of patients at very low risk of resistance. In the field, the experience is that 0,1-0·2% of patients relapse at some time after completing MDT. Although these proportions are small, the absolute numbers of relapses may be quite large in some countries. The vast majority of these patients have been reported to respond to retreatment by the same regimen. Therefore, they represent problems of microbial persistence rather than drug resistance. I believe the test should be applied only to those patients who fail to respond to retreatment, thereby avoiding dilution of the cohort at greatest risk and avoiding the problem of false positives.
Dr Klatser: Dr Roche, did you exclude false positives as the result of amplicon amplification in the cases in which you detected mutations in the face of susceptibility to rifampicin in the mouse?
Dr Roche: These cases occurred early in our study. Since then, we have examined a large number of strains, without encountering any more of these cases. If we had been dealing with amplicons amplification, we should have continued to find new cases.
Dr Dockrell: Surely, the chance to obtain false-positive results in a peR in which one loses hybridization to one product and gains it to another is really quite small.
